


Akeso Biomedical Email Formats
Biotechnology Research • Waltham, Massachusetts, United States • 1-10 Employees
Akeso Biomedical Email Formats
Akeso Biomedical uses 1 email format. The most common is {first initial}{last name} (e.g., jdoe@akesobiomedical.com), used 100% of the time.
| Format | Example | Percentage |
|---|---|---|
{first initial}{last name} | jdoe@akesobiomedical.com | 100% |
Key Contact at Akeso Biomedical
Simon Williams
Chief Executive Officer
Company overview
| Headquarters | 850 Winter Street, Waltham, MA 02451-1420, US |
| Phone number | +17818900088 |
| Website | |
| NAICS | 541714 |
| SIC | 873 |
| Keywords | Microbial Biofilms, Chronic Wounds. |
| Founded | 2014 |
| Employees | 1-10 |
| Socials |
About Akeso Biomedical
Akeso Biomedical, Inc. is an early stage company focused on developing new solutions for the treatment of bacterial infections, microbial biofilms, and chronic wounds. The Company is developing products to treat these conditions using a new class of compounds, known as Fe3C, that have broad-spectrum activity against a wide range of bacteria, and a silk biomaterial technology exclusively licensed from Tufts University. Akeso’s lead Fe3C product is a feed additive designed to prevent food poisoning by Campylobacter, a bacteria that causes more cases of foodborne illness in the EU than Salmonella, E. coli and Listeria combined, with an estimated 280,000 cases in the UK and 1.3 million cases in the US each year. The economic cost of treating patients infected with Campylobacter in the UK is reported to be $1.5 billion, and over $5.6 billion in the US.
Employees by Management Level
Total employees: 1-10
Seniority
Employees
Employees by Department
Akeso Biomedical has 1 employees across 1 departments.
Departments
Number of employees
Akeso Biomedical Tech Stack
Discover the technologies and tools that power Akeso Biomedical's digital infrastructure, from frameworks to analytics platforms.
Web servers
Tag managers
Analytics
Font scripts
Frequently asked questions
4.8
40,000 users



